CVMP opinions on veterinary medicinal products

The Committee adopted a positive opinion for a marketing authorisation for Emepax (maropitant), indicated for the prevention of nausea induced by chemotherapy, for vomiting induced by motion sickness, prevention and for treatment of vomiting in dogs. The product is to be used in conjunction with maropitant solution for injection and in combination with other supportive measures.

The Committee adopted a positive opinion for a variation for Bluevac BTV (Bluetongue virus vaccine (inactivated)) to allow up to three different inactivated bluetongue virus serotypes to be included in the final vaccine.

The Committee adopted a positive opinion for a variation for Suvaxyn PRRS MLV (porcine respiratory and reproductive syndrome virus vaccine (live)) to introduce the possibility of using a needle-free device to administer the product (0.5 ml dose) via the intramuscular route in pigs for fattening.

The Committee adopted a positive opinion…